The value of fibrinolytic enhancement with an anabolic steroid (stanozolol) combined with elastic stockings in treating venous lipodermatosclerosis was assessed in a six-month double-blind cross-over trial. Thirty-four legs of 23 patients in whom other treatments had failed were studied. The patients were randomly divided into two groups who were treated with either stanozolol plus elastic stockings or placebo plus elastic stockings for three months, and then vice versa. Treatment with or without stanozolol caused the area of lipodermatosclerosis to decrease, but the rate of healing when patients took stanozolol was double that when they took the placebo, and this was assumed to be biologically important. Stanozolol also reduced the incidence of extravascular fibrin detected in skin biopsy specimens. The elastic stockings with placebo produced significant decreases in leg volume, ankle circumference, and skin thickness.
was based on the detection of pericapillary interstitial cuffs of fibrin that, by acting as a diffusion barrier, appeared to be the ultimate cause of vcnous ulceration. 2 The results of this pilot study encouraged us to conduct a double-blind cross-over clinical trial to assess the value of stanozolol in the treatment of venous liposclerosis, which is oftcn resistant to other methods of treatment. This trial compared the cffect of stanozolol and elastic stockings with the effect of elastic stockings and placebo on the rate of resolution of the area of liposclerosis. It was not a study of the healing of venous ulceration.
Patients and methods PATIENT SELECTION In the pilot study' we selected a group of patients who had bcen attending our vein clinic for some years and added stanozolol to their treatment, leaving all other treatments unchanged. All these patients had stopped using elastic stockings. In the present trial we wished to studv recently referred patients in whom conventional operations had failed. Wle did not think that it was ethically justifiable to withhold the usc of elastic stockings; consequently all patients were prescribed new, properly fitted below-knee Sigvaris elastic stockings, and the trial compared the effect of elastic stockings plus placebo tablets-that is, elastic stockings alone-with the effect of elastic stockings plus stanozolol.
Recently referred patients presenting at the clinic who had had no operations for at least one year and for whom no further operations were contemplated, and who had active liposclerosis but no venous ulceration, were asked to participate in the trial. Informed written consent was obtained from all paticnts.
PATIENT ASSESSMENT A full clinical history was recorded, with particular attention being paid to the patient's age, sex, weight, history of leg disease and deep vein thrombosis, family history, and smoking habits. The state of the leg disease was assessed from the history and the results of the following tests.
Area of liposclerosi's The edge of the liposclerosis was determined by careful inspection and palpation and marked with a fine felt-tip pen. The enclosed area was measured by placing a piece of standardweight tracing paper over the leg, tracing the marked edge on to the paper, cutting out the enclosed area of paper, weighing it, and converting this result into a measurement of area by using the known weight of 1 cm' of paper. Every area was calculated by the same observer without knowledge of either the shape or size of the area when measured before, or of the form of treatment. The reliabilitv of the method was tested by measuring 10 areas of liposclerosis on two separate occasions, the observer having no knowledge of the size of the first measurement when determiiining the second. The mean of' the first 10( measurenments was 73-3 cm' and of the second 76-7 Cmil'2 a difference of 4 5'', Zlean circumferences of the two sets of measurements were 32 3 and 3306 cm respectively, a difference of 4", When individual pairs of measurements were exaimlined the second mleasurement of area was from -3",, to 17',, greater than the first (mean 7",, ). The second measurement of circumfercnce was from -7, to 15",i greater thain the first (mean 6,8',,) . This technique of measureimient thus had an overall accuracy within the range 10',, for both area and circumference, and any changc between pairs of measuremiients or means of groups of measurements ox-er 20 '0" was regarded as significant.
Cluinilcal photo,graplns were taken in black and white, colour, and infrared with the leg in a standard position to provide a permanent record of' the changes that occui-rcd during the trial.
CirciOiifl-creiice o the leg' was imieasured at a point 10 cmil above the Imledial ialleolus.
Lg,, volitnne was measui ed by water displacement to a constant levCel, 45-7 cm (18 in) above the sole.
Skii tlnickmeos was measured on the Imiedial side of the leg, 102 cIll 4 in) above the nmedial imialleolus, using soft-tissue radiography.
/Skin bio)pi spcei,Oies for assessing capillary prolif'eration and extravascular hibrin depositioin' were taken from a point 7-5 cii above the medial imialleolus. The assessor-(the late Dr-I Whimster) had no knowledge of' the form of treatmicnt.
Foot veini prestInoes xx cre measured at rest anid during maximal hcelraising exercise before and at the end of the tIial.
GenerlV blood stodiCS such as haiacimoglobin concentration, packed cell volunme, plasma protein concentrations, and liver-function tests wcivc perf'oi mied by the usual pathology services. Speca/l blood1 tests-Blood wras takcn bctxxeen 0030 and 103(0 by clean vein puncture without congestion, in the f'astinig state, for meeasurement of plasmia fibrinogen concentration by the clot-weight method' anid dilute blood clot lysis time (DBCLT)." BRITISH MEDICAL JOURNAI, JANUARY 1980 present for a mean of 22 years (range 6-50). The symptoms and signs of liposclerosis (eczema, pigmentation, pain, and induration) Four of the nine patients who began w,vith placebo and elastic stockings had unilateral disease and five had bilateral disease, giving 14 legs for analysis; and eight of the 14 patients who began with stanozolol and elastic stockings had unilateral disease and six had bilateral disease, giving 20 legs f'or analyrsis. Thus 34 areas of liposclerosis were studied during the six-month trial. Figure 1 shows the changes in the mean areas of liposclerosis in the two groups. Figure 2 comllbines these results, ignoring the possibility that the response in the second three months might have been affected by the response in the fir-st three months. Figure 3 compares the mieans of the areas that wvere healed by the two forms of treatment. The mean area of healing during treatment with stanozolol and elastic stockings was 155 mm' (SE of mean 40) conmpared with 78 mm' (SE of mean 15) during treatment with placebo and elastic stockings. An unpaired t test showed that the probability that this was not a chance difference was 90",,. This is not usually regarded as a statistically significant difference, but we believe that this difference was biologically important. The beneficial effect of the stanozolol was blurred by using elastic stockings, which were effective in their own right.
LIPOSCLEROSIS
The increased rate of healing xxith stanozolol occurred whether it was given in the first or second three months of treatment (fig 1) .
In both groups of patients the area that healed doubled when they were taking stanozolol (173 mm2 conmpared with 83 mm2 and 130 mm' compared with 72 mm' respectively). The changes in the areas of liposclerosis for both forms of treatment at three and six months were significant when both groups were considered separately (fig 1) began treatment with stanozolol plus elastic stockings and decreased significantly when they changed to placebo and elastic stockings.
There was a similar, but non-significant, reduction in ankle circumference in the patients who began treatment with placebo plus elastic stockings, but there was no change when this group changed to stanozolol.
The skin 10 2 cm (4 in) above the medial malleolus of the patients who were given stanozolol first became thicker but then showed a significant thinning during treatment with placebo and elastic stockings. The skin thickness of the patients who took placebo first and then stanozolol showed no significant change.
BLOOD CHANGES
The haemioglobin and plasma protein concentrations showed no significant changes throughout the trial. The only liver-function test result to change during treatment with stanozolol was serum aspartate transaminase (serum AST; SGOT) activity. In 15 of the 23 patients it did not alter; in five it rose from a mean of 50 units to a mean of 78 units (range 70-90; normal range 25-65); and in three it rose to 115, 125, and 140 units respectively but fell to normal levels within one month of changing to placebo. Three patients showed a slight increase in their serum creatinine concentrations.
Mean plasma fibrinogen concentration fell significantly during treatment with stanozolol plus elastic stockings and rose significantly when stanozolol was stopped ( fig 5) . The group that took placebo Coonz-cir)on: SI to tr-aditi^onial ionits-Plasma fibrinogen concentration: 1 g 1 100 mg 100 ml.
for the first three months showed no change in mean plasma fibrinogen concentrationi during this time. TIheir mean plasma fibrinogen concentIation Cell during the second three months, when they were taking stanozolol, but this fall did not reach significance (P= 009).
The mean DBC LT fell significantly for the first threc Iionths in the patients who began treatment with stanozolol and rose significantly during this time in the patients who began treatment with placebo.
The other changes in DBCLT ( fig 5) were in the expected direction but did not achieve significancc. This was almost certainly because of the wide natural variations in DBCLT anid the small numbers of patients studied. SKIN HiISTOLOGY £ he biopsv .speciniiens were studied to assess the number of skin capillaries and the incidence of extravascular fibrin. Biopsies were performed before treatment aind at three and six months on 34 legs.
Capillary proliferation was divided into four grades of severity normal, mild, moderate, and severe-and converted into numerical scores O, 1, 2, and 3 respccti1vlv). The mean capillary proliferation scores for each group of patients whether receiving stanozolol or placcbo decreased stcadily throughout the trial (fig 6) . Over the whole six months the mean score of all patients fell from 2- As we had to treat a group of patients in wshom conventional treatment had failed we thought it reasonable to asscss the effect of stimulating the fibrinolytic system with stanozolol. A pilot studvy indicated that this would be worth while, and we set up a double-blind cross-over trial to test this drug.
The major problem was assessing the liposclerosis. Measuring an indurated tender area of skin and subcutaneous tissue is difficult. We chose our method of measurement because it was simple, direct, and reproducible to within 10",,. Other methods of assessing healing, such as percentage change or those cntailing calculations of area and perimeter length, appeared to offer no advantages.
To gain as much information as possible about the leg we measured leg circumference, leg volume, skin thickness, and foot vein pressure and assessed skin histology (for capillary proliferation and extravascular fibrin). These additional measurements were particularly relevant to the mechanical effects of the elastic stockings, which we felt ethically obliged to include in our treatment regimen.
Stanozolol prolonged the mean DBCLT and reduced mean plasma fibrinogen concentrations; blood fibrinolysis was, therefore, enhanccd. This confirrms the results of other studies of stanozolol.'0 1' Unfortunately stanozolol takes four weeks to produce this effect, and after stopping trcatmcnt the effect takes four weeks to wear off. This makes interpretation of the rcsults in the second three-month period for those who took stanozolol in the first three months difficult, because for at least one month of their treatment with placebo their blood fibrinolysis was still partially enhanccd. Without this "hangovcr" effect some of the rcsults that only just reached significance might have been more significant.
Both placebo plus elastic stockings and stanozolol plus elastic stockings produced a highly significant reduction in the mean area of liposclerosis (P =0 001). The mean rate of healing was twice as great wvhen the patients were taking stanozolol, but the statistical probability that this difference was caused by the drug was only 90(),. Nevertheless, we believe that this is a biologically important difference because of the other changes that occurred when the patients took stanozolol such as rapid alleviation of pain and tenderness, and particularly the loss of skin pigmentation, which did not occur in the period of treatment with placebo. Thesc differences were impossible to quantifv, but, since the mean healing rate doubled (figs 1, 2, and 3), we are certain that stanozolol had a real, significant, and independent effect, which was also apparent in our pilot study in which clastic stockings wvere not used.' Our present study did not include a group of subjects who were not treated because all the patients had been specially referred to our clinic from other centres because their liposclerosis was deteriorating or had tailed to respond to other treatment. Spontaneous improvement was, therefore, unlikely, and we thought that a "non-treatment" group was unjustifiable.
By causing minor fluid retention stanozolol opposed the effect of the elastic stockings in reducing mean leg volume and circumfcrence but not to the extent that the mean leg volume increased. Placebo plus elastic stockings-that is, elastic stockings alone-caused a significant reduction in mean leg volume.
All biopsies showved some capillary proliferation. group. Thcrcr was also a reduction in the number of bIiops specimens containing fibrin taken from those patients treated with placebo plus elastic stockings for the second thrcc months of the trial, but whether thiis was a hangover cffect from the previouLS three months of taking stanozolol or an clffct caused by the elastic stockings is impossiblc to say. It is unlikely to havc bccn cauisd by the stockings becaLuse it did not occur in thos wlho bcgan treatimecnt with placebo and stockings.
The imecan exercising loot vein presstures were unaltered by the trial. This confirimied that the treatment caLuscd no 'tindamental change in the etlicicncy ot the calt mu>scle pump, thouLgh pUmIlp t'tnction was certainly changed while the elastic stockings were being worn.'
The side etfects of treatimeznt were slight and did not cause anyone to stop treatmlent. Liver-function test abnormallities were minor and resolved spontaneously.
All blut one patient believed that their legs had improvcd but wesre unablc to differentiate betwcen the effect of placebo and that of stanozolol except f'or the effesct on pain. The btirning discom-fort that somc patients suffercd in the area of liposcleiosis eased within thrce to four weeks aftcr beginning stanozolol. All patients wanted to continuc treatment with stanozolol aftcr the trial had ended. Thc long-term results have been encouraging and will be the subjcct of a further report. In almost every patient the induration has disappearcd af'ter six to nine months of trcatimecnt, and in many the brown pigmentation has also regressed. \W'c have stopped giving stanozolol aftcr 12 months of' treatnment, and so f'ar the legs have rcnained hcalthy wsith the use of good elastic stockings.
Stanozolol is a usetf'ul addition to the trcatment of venous liposclerosis, but we advise that it is uscd only in intractable cascs in which other mewthods of trcatment have f'ailcd. Stanozolol takes at least three months to produce a worthwhile response and nine to 12 months to achieve its maxim1-um-i effect. During this tiIie the patient should be observed carefully for evidence of excessive water rctention or masculinisation, and liverf'unction tests and nmcasureimeicnts of' plasimia fibrinogen concentrations conducted regUtlarly. Stanozolol nmav be assumed to be enhancing fibrinolvsis it' the plasmna fibrinogen concentration falls, b1ut administration should be stopped if' AST activitv rises above 120 units.
The clinical response of liposclerosis to fibrinolytic enhancenment and the histological evidence ot' a redduction in the quantity of extravascular fibrin in the skin of somc patients after only three months of treatment with stanozolol suipport our hypotheses on the actiology of v-enous ulceration. 
